Drug Profile
Research programme: kallikrein inhibitors - Verseon
Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Verseon
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Hereditary angioedema
Most Recent Events
- 08 Sep 2022 Preclinical development is ongoing for hereditary angioedema and diabetic macular edema in USA
- 08 Sep 2022 Verseon has granted patent protection covering novel chemical matter for plasma kallikrein inhibitors in Europe
- 28 Oct 2021 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (PO)